OncoHost is advancing a new paradigm in precision oncology
Our PROphet® platform combines bioinformatics, system biology, proteomic pattern recognition and machine learning to assign a PROphet® score, a measure of the predicted clinical benefit from
PD-1/PD-L1 inhibitors correlated to the patient’s overall survival, and list clinical evidence-based treatment considerations.
Understanding the interplay between
Cancer, Patient & Therapy
A new dimension to personalization
Watch now
A new approach to managing PD-1/PD-L1 inhibitor therapeutic strategies
Blood-based test
Personalized
PROphet® Report
Predictive
clinical insights
Clinical evidence-
based treatment considerations
Learn more about PROphet® in this ISLB webinar featuring:
Prof. David Gandara
Prof. David Carbone
Plasma Proteomic
Pattern Recognition
Analyzing the biological interplay between the patient, tumor, and therapy can:
Enable early prediction of clinical benefit from PD-1/PD-L1 inhibitors
Provide actionable clinical insights and optimal therapy choices
Read more
